Healthcare [ 2/11 ] | Biotechnology [ 32/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 2, 22 | -0.58
Decreased by
-1.75%
|
-0.64
Increased by
+9.38%
|
Aug 9, 22 | -0.52
Increased by
+1.89%
|
-0.61
Increased by
+14.75%
|
May 4, 22 | -0.56
Decreased by
-124.00%
|
-0.58
Increased by
+3.45%
|
Feb 23, 22 | -0.54
Decreased by
-1.89%
|
-0.60
Increased by
+10.00%
|
Nov 4, 21 | -0.57
Decreased by
-9.62%
|
-0.56
Decreased by
-1.79%
|
Aug 4, 21 | -0.53
Increased by
0.00%
|
-0.55
Increased by
+3.64%
|
May 5, 21 | -0.25
Increased by
+50.00%
|
-0.46
Increased by
+45.65%
|
Feb 25, 21 | -0.53
Increased by
+8.62%
|
-0.56
Increased by
+5.36%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 49.00 K
Increased by
0.00%
|
-83.15 M
Decreased by
-6.35%
|
Decreased by
-169.69 K%
Decreased by
-6.35%
|
Jun 30, 22 | 0.00
Decreased by
-100.00%
|
-74.79 M
Decreased by
-5.43%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 61.00 K
Decreased by
-99.84%
|
-79.85 M
Decreased by
-141.86%
|
Decreased by
-130.90 K%
Decreased by
-151.93 K%
|
Dec 31, 21 | 51.00 K
Increased by
+N/A%
|
-74.87 M
Decreased by
-9.18%
|
Decreased by
-146.80 K%
Decreased by
N/A%
|
Sep 30, 21 | 49.00 K
Increased by
+N/A%
|
-78.19 M
Decreased by
-18.11%
|
Decreased by
-159.56 K%
Decreased by
N/A%
|
Jun 30, 21 | 44.00 K
Increased by
+N/A%
|
-70.94 M
Decreased by
-16.34%
|
Decreased by
-161.22 K%
Decreased by
N/A%
|
Mar 31, 21 | 38.34 M
Increased by
+N/A%
|
-33.02 M
Increased by
+39.40%
|
Decreased by
-86.10%
Decreased by
N/A%
|
Dec 31, 20 | 0.00
Decreased by
N/A%
|
-68.57 M
Decreased by
-12.35%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.